Improved reporting gives greater insight into the business, but investors are still left with little visibility into potential downstream value. Ginkgo needs to demonstrate that they are more than a ...

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning. What's behind ...

Ginkgo Bioworks announces a partnership to work with Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity. The company also announces the acquisition of AgBiome's ...

Ginkgo Bioworks is a company with a lot of potential but also a lot of associated risk. The company is having difficulty growing revenues and is experiencing large operating losses. There are some ...

Could Ginkgo Bioworks Holdings (NYSE: DNA) one day be part of the healthcare sector's version of the "Magnificent Seven" group of high-performing stocks? It's more likely than you think. The ...

"It's a great opportunity to get to work with the PREDICTS team led by Deep Origin," said Jesse Dill, Senior Director at ...

Forbes contributors publish independent expert analyses and insights. Benjamin Wolff covers leadership insights from the world of the arts. A new technology is changing the world, turning dreams into ...

Ginkgo Bioworks announces the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo Bioworks shares are up more than 9% over the past week. Get 5 ...